Category: CovidienSyndicate content

Med-tech tax: Covidien CFO calls levy "just another business issue that we will deal with"

January 26, 2012 by MassDevice staff

Charles Dockendorff, CFO of Covidien Plc., tells investors that the impending medical device tax will affect about half of the company's total sales.

Covidien

Covidien plc (NYSE:COV) officials aren't predicting any doomsday scenarios for the incoming medical device tax.

In a conference call with investors Thursday, company CFO Charles Dockendorff called the tax "just another business issue" the company would manage as it moves forward.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Heart docs claim harassment for exposing poor patient care | Legal News

January 26, 2012 by MassDevice staff

A quartet of California cardiologists filed suit against a county hospital, claiming that they were persecuted and forced out of their jobs after exposing inadequate patient care.

Doctors Singh and Ihnken

Drs. Singh and Ihnken

A group of California cardiologists filed a lawsuit against Santa Clara Valley Medical Center, alleging that they were harassed out of their jobs after they complained about a pattern of compromised patient safety at the hospital.

The plaintiffs are led by echocardiographer Dr. Geeta Singh and cardiothoracic surgeon Dr. Kai Ihnken, with 2 additional cardiologists named alongside them in the lawsuit.

Covidien posts a record-breaking quarter, ups guidance for 2012

January 26, 2012 by MassDevice staff

Covidien shares jump on Wall Street after it raises its outlook for 2012 and posts a Street-beating quarter of record-breaking adjusted gross margins.

Covidien logo

Covidien plc (NYSE:COV) was in Wall Street's good graces this morning after beating expectations and boosting its 2012 fiscal guidance.

The Mansfield, Mass.-based company touted record adjusted gross margins of 58.8% for the 3 months ended Dec. 24, 2011, 1.2 points higher than during the same period in 2010.

Covidien also upped its 2012 fiscal guidance, forecasting 3% to 5% sales growth. Its previous guidance was about a point lower.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +3 | The top 3 med-tech stories for January 23, 2012

January 23, 2012 by MassDevice staff

St. Jude responds to a summit on the recall of its Riata defibrillator leads, Boston Scientific fights the hype on deformation concerns on its thinner stents and Covidien announces a new head for its $1.4 billion global vascular therapies business.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

GPOs: Premier, Child Health Corp. ink new deals

January 23, 2012 by MassDevice staff

Group purchasing organization Premier and Child Health Corp. ink a slew of new supply deals for medical device products.

Group purchasing organization Premier said it signed a raft of supply deals for a variety of medical device products.

The Charlotte-based GPO said it signed deals for endomechanical, trocar, suture and topical skin adhesives with 16 companies.

Covidien names new vascular leader | Personnel Moves

January 23, 2012 by MassDevice staff

Covidien taps Stacy Enxing Seng, a former executive from its ev3 acquisition, to lead its vascular therapies business; also, Aethlon Medical sets up advisory board; AtriCure hires Lux to be COO; and Sirona Dental loses 2 board members.

Covidien press release

Covidien (NYSE:COV) named Stacy Enxing Seng president of its $1.4 billion global vascular therapies business.

Enxing Seng, 47, will lead the division's 4,000 employees, reporting to Peter Wehrly, president of the Mansfield, Mass.-based firm's respiratory & monitoring solutions and vascular therapies division. She joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization treatment for cerebral aneurysms.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +7 | The top 7 med-tech stories for the week of January 16, 2012

January 21, 2012 by MassDevice staff

Deaths spur Covidien recall, J&J warned on insulin pumps, Depuy shuts down custom devices, CEOs claim emerging markets, thought-leaders huddle on Riata, more J&J execs deposed and Stryker settles for $15M this week.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp